JP2006506469A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506469A5
JP2006506469A5 JP2005507130A JP2005507130A JP2006506469A5 JP 2006506469 A5 JP2006506469 A5 JP 2006506469A5 JP 2005507130 A JP2005507130 A JP 2005507130A JP 2005507130 A JP2005507130 A JP 2005507130A JP 2006506469 A5 JP2006506469 A5 JP 2006506469A5
Authority
JP
Japan
Prior art keywords
mir15
gene product
mir16
use according
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005507130A
Other languages
English (en)
Japanese (ja)
Other versions
JP4939055B2 (ja
JP2006506469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/035777 external-priority patent/WO2004043387A2/en
Publication of JP2006506469A publication Critical patent/JP2006506469A/ja
Publication of JP2006506469A5 publication Critical patent/JP2006506469A5/ja
Application granted granted Critical
Publication of JP4939055B2 publication Critical patent/JP4939055B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2005507130A 2002-11-13 2003-11-12 癌の診断および治療のための組成物および方法 Expired - Fee Related JP4939055B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42586402P 2002-11-13 2002-11-13
US60/425,864 2002-11-13
US46946403P 2003-05-09 2003-05-09
US60/469,464 2003-05-09
PCT/US2003/035777 WO2004043387A2 (en) 2002-11-13 2003-11-12 Compositions and methods for cancer diagnosis and therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011102656A Division JP2011225570A (ja) 2002-11-13 2011-05-02 癌の診断および治療のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2006506469A JP2006506469A (ja) 2006-02-23
JP2006506469A5 true JP2006506469A5 (https=) 2010-09-16
JP4939055B2 JP4939055B2 (ja) 2012-05-23

Family

ID=32314611

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005507130A Expired - Fee Related JP4939055B2 (ja) 2002-11-13 2003-11-12 癌の診断および治療のための組成物および方法
JP2011102656A Pending JP2011225570A (ja) 2002-11-13 2011-05-02 癌の診断および治療のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011102656A Pending JP2011225570A (ja) 2002-11-13 2011-05-02 癌の診断および治療のための組成物および方法

Country Status (8)

Country Link
US (4) US20040152112A1 (https=)
EP (1) EP1567007B1 (https=)
JP (2) JP4939055B2 (https=)
CN (1) CN102304570B (https=)
AT (1) ATE546528T1 (https=)
AU (1) AU2003291433B2 (https=)
CA (1) CA2504605C (https=)
WO (1) WO2004043387A2 (https=)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504605C (en) * 2002-11-13 2016-01-19 Thomas Jefferson University Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
CA2554818A1 (en) 2004-02-09 2005-08-25 Thomas Jefferson University Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features
JP5697297B2 (ja) 2004-05-14 2015-04-08 ロゼッタ ジノミクス リミテッド マイクロｎａｓおよびその使用
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
EP2290073A3 (en) 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
EP2338994B1 (en) * 2004-09-02 2014-03-19 Yale University Regulation of oncogenes by microRNAs
EP2302055B1 (en) 2004-11-12 2014-08-27 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
US8192938B2 (en) 2005-02-24 2012-06-05 The Ohio State University Methods for quantifying microRNA precursors
CN103820562B (zh) * 2005-08-01 2015-05-13 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
WO2007028030A2 (en) * 2005-09-02 2007-03-08 Picobella, Llc Oncogenic regulatory rnas for diagnostics and therapeutics
JP2009507918A (ja) * 2005-09-12 2009-02-26 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法
US20090270484A1 (en) * 2005-10-05 2009-10-29 The Ohio State University Research Foundation WWOX Vectors and Uses in Treatment of Cancer
ES2553442T3 (es) * 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
EP1969147B1 (en) * 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
AU2012238336B8 (en) * 2006-01-05 2014-08-07 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2016203848B2 (en) * 2006-01-05 2017-12-14 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
AU2014203454B2 (en) * 2006-01-05 2016-03-17 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
EP2522746B1 (en) * 2006-03-02 2014-11-12 The Ohio State University Research Foundation MicroRNA expression profile associated with pancreatic cancer
EP2369011A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Microrna fingerprints during human megakaryocytopoiesis
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2007147067A2 (en) * 2006-06-14 2007-12-21 Rosetta Inpharmatics Llc Methods and compositions for regulating cell cycle progression
EP2041317A4 (en) 2006-07-13 2009-10-14 Univ Ohio State Res Found METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES
EP2061907B1 (en) 2006-09-19 2011-11-23 The Ohio State University Research Foundation Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181
AU2007299804A1 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. MiR-200 regulated genes and pathways as targets for therapeutic intervention
US8252538B2 (en) 2006-11-01 2012-08-28 The Ohio State University MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
EP2102341A2 (en) * 2006-12-08 2009-09-23 Asuragen, INC. Mirna regulated genes and pathways as targets for therapeutic intervention
JPWO2008090930A1 (ja) * 2007-01-23 2010-05-20 オリンパス株式会社 癌の診断方法
WO2008094545A2 (en) 2007-01-31 2008-08-07 The Ohio State University Research Foundation Mic orna-based methods and compositions for the treatment of acute myeloid leukemia
US20100111873A1 (en) 2007-02-20 2010-05-06 Russell Stephen J Treating cancer with viral nucleic acid
KR20100027102A (ko) * 2007-04-10 2010-03-10 내셔널 타이완 유니버시티 마이크로ｒｎａ를 이용한 암환자의 치료 후 생존을 예측하는 방법
AU2008248319B2 (en) * 2007-04-30 2013-09-05 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
ES2537349T3 (es) * 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar un subtipo de carcinoma hepatocelular
CN101918424A (zh) 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
CN101809169B (zh) 2007-07-31 2013-07-17 俄亥俄州立大学研究基金会 通过靶向dnmt3a和dnmt3b恢复甲基化的方法
EP2653561B1 (en) 2007-08-03 2016-03-02 The Ohio State University Research Foundation Ultraconserved regions encoding ncRNAs
EP3028708A1 (en) 2007-08-22 2016-06-08 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP2775001B1 (en) * 2007-09-06 2016-03-09 The Ohio State University Research Foundation MicroRNA signatures in human ovarian cancer
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
MX2010003371A (es) 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
EP2212440A4 (en) * 2007-10-11 2011-04-06 Univ Ohio State Res Found METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF ADENOCARCINOMES OF DISHES
CA2703707A1 (en) 2007-10-26 2009-04-30 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (fhit) interaction and uses thereof
KR20100099158A (ko) 2007-11-09 2010-09-10 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근세포 생존과 심장 회복을 제어하는 ＭＩＲ-15 집단의 마이크로ＲＮＡｓ
CN101918594A (zh) * 2007-11-30 2010-12-15 俄亥俄州立大学研究基金会 肺癌中外周血中的微rna表达特征谱和靶向
WO2009070805A2 (en) 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
CA2717026A1 (en) * 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
CN102027129B (zh) * 2008-02-28 2014-03-12 俄亥俄州立大学研究基金会 用于前列腺相关病症的诊断、预后和治疗的基于微rna的方法和组合物
WO2009111643A2 (en) * 2008-03-06 2009-09-11 Asuragen, Inc. Microrna markers for recurrence of colorectal cancer
EP2271757A2 (en) * 2008-03-26 2011-01-12 Asuragen, INC. Compositions and methods related to mir-16 and therapy of prostate cancer
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
EP2307028B1 (en) 2008-06-11 2013-10-02 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy
WO2010045318A2 (en) * 2008-10-14 2010-04-22 Caris Mpi, Inc. Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
US7888035B2 (en) * 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
GB2465088C (en) * 2008-10-30 2016-01-27 Caris Mpi Inc miRNA expression in the characterisation and classification of cancer
WO2010056337A2 (en) * 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
US8883995B2 (en) 2009-03-06 2014-11-11 Icahn School Of Medicine At Mount Sinai Live attenuated influenza virus vaccines comprising microRNA response elements
WO2011040613A1 (ja) 2009-10-01 2011-04-07 独立行政法人国立がん研究センター 腫瘍治療剤
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
US8664192B2 (en) 2011-03-07 2014-03-04 The Ohio State University Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
EP2766500A4 (en) 2011-10-14 2015-10-14 Univ Ohio State METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER
AU2012352265B2 (en) 2011-12-13 2017-02-16 Ohio State Innovation Foundation Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis
WO2013106766A2 (en) * 2012-01-13 2013-07-18 The Research Foundation Of State University Of New York THERAPEUTIC INDICATIONS OF miR-1291
US8859202B2 (en) 2012-01-20 2014-10-14 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
WO2014030602A1 (ja) 2012-08-20 2014-02-27 独立行政法人国立がん研究センター 癌治療剤
US10287633B2 (en) 2013-11-06 2019-05-14 Universite De Rennes 1 TYRP1, a natural miRNA sponge, and its use in managing human melanoma aggressiveness
CN104846086A (zh) * 2015-05-04 2015-08-19 四川大学华西第二医院 血浆miR-15b作为分子标记物在精子产生与功能评估中的应用
CN109295231A (zh) * 2017-11-03 2019-02-01 中国医学科学院基础医学研究所 Nok基因在慢性b淋巴细胞白血病诊断或治疗中的用途
IL299826A (en) 2020-07-15 2023-03-01 Cerebral Therapeutics Inc A medical device with a non-filtered CSF withdrawal path
US12605537B2 (en) 2022-02-15 2026-04-21 Biogen Ma Inc. Implantable medical device for use with or having recording electrode
WO2023249888A1 (en) * 2022-06-21 2023-12-28 Curamir Therapeutics, Inc. Cytarabine-modified mirna for treating cancer
EP4417285A1 (en) * 2023-02-16 2024-08-21 Sartorius BIA Separations d.o.o. Method for purification of lipid nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6140049A (en) * 1996-11-21 2000-10-31 Genset Detection and early diagnosis of prostate cancer
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP2447370B1 (en) * 2001-09-28 2018-07-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
AU2003291281A1 (en) * 2002-11-01 2004-06-07 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CA2504605C (en) 2002-11-13 2016-01-19 Thomas Jefferson University Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15
US7851150B2 (en) * 2002-12-18 2010-12-14 Third Wave Technologies, Inc. Detection of small nucleic acids
JP4230457B2 (ja) 2002-12-18 2009-02-25 サード・ウェーブ・テクノロジーズ・インク 低分子核酸の検出方法
JP2006519008A (ja) * 2003-02-10 2006-08-24 独立行政法人産業技術総合研究所 哺乳動物細胞の調節
JP2007512805A (ja) 2003-10-14 2007-05-24 ノバルティス　アクチエンゲゼルシャフト オリゴヌクレオチドマイクロアレイ

Similar Documents

Publication Publication Date Title
JP2006506469A5 (https=)
US11661596B2 (en) Targeted RNA editing by leveraging endogenous ADAR using engineered RNAs
US7763590B2 (en) Compositions and methods for inhibiting expression of a mutant gene
CN102304570B (zh) 用于癌症诊断和治疗的组合物和方法
US8273870B2 (en) Compositions and methods for inhibiting expression of a mutant gene
EP2147103B1 (en) Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
AU702373B2 (en) Stabilized external guide sequences
JP6141018B2 (ja) 炎症性障害を治療するための分子
US10927373B2 (en) Compositions and methods for inhibiting gene expression of Hif2alpha
US9044506B2 (en) MIR-21 promoter driven targeted cancer therapy
US20240309368A1 (en) Targeted rna editing by leveraging endogenous adar using engineered rnas
JP2025072578A (ja) Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
KR101420564B1 (ko) ＴＧＦ－β２ 발현을 억제하는 ｓｈＲＮＡ
WO2011065677A2 (ko) 암 치료용 약학 조성물
US20240175031A1 (en) Treatment of mst1 related diseases and disorders
WO2023220719A2 (en) Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting
KR101374585B1 (ko) ＨＳＰ２７ 발현을 억제하는 ｓｈＲＮＡ
Shen et al. Multi-ribozyme targeting of human α-globin gene expression
KR20210121079A (ko) 종양 치료를 위한 올리고뉴클레오티드 분자 및 그의 이용
CN1055968C (zh) 大肠杆菌胞嘧啶脱氨酶基因及含该基因的新实体
CN121975801A (en) Multiplex shRNA combinations and uses thereof
CN117460826A (zh) 靶向FAP阳性细胞的siRNA缀合物及其药物组合物和应用
CN107278229A (zh) 用于治疗胰岛素抵抗的靶向转录因子tsc22d4的寡核苷酸序列
HK40071185A (en) Use of sept9 inhibitors for treating hepatitis b virus infection
Farooqi Physiology to the Pleiotropic Role of RNAs: Prospecting Novel Therapies